Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Slides:

Advertisements

Similar presentations

Effects of highly concentrated SFN provided as BSE in T2D patients

Advertisements

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Improvement in the transcriptional activity of FOXP3A384T by enhancement of TIP60-FOXP3 interaction. Improvement in the transcriptional activity of FOXP3A384T.

Role of TLR signaling in hY4-induced changes and effects of TLR inhibition. Role of TLR signaling in hY4-induced changes and effects of TLR inhibition.

a b c d OGTT OGTT *** ** * * Blood glucose (mg/dL) AUC (mg/dL/min) ND

Fig. 7 Correlation of NHP and human ISGs.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 1 Movement percepts for all participants.

AMPK-mediated mTORC2 signaling does not require mTOR Ser1261phosphorylation. AMPK-mediated mTORC2 signaling does not require mTOR Ser1261phosphorylation.

Fig. 4 Labeling of Msmeg with DMN-Tre is fast and specific and depends on Ag85A function. Labeling of Msmeg with DMN-Tre is fast and specific and depends.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Microrobots with different cell-carrying capacities under different grid lengths (lg) and burr lengths (lb). Microrobots with different cell-carrying capacities.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Adipose tissue dysfunction induces increased liver HIF-1α expression

Fig. 2 HHKO mice exhibit improved glucose tolerance by increasing plasma incretin levels and insulin secretion. HHKO mice exhibit improved glucose tolerance.

Fig. 4 Deletion of hepatocyte HIF-2α does not affect obesity-induced glucose, glucagon, and insulin intolerance. Deletion of hepatocyte HIF-2α does not.

Fig. 3 Glucose- and structure-dependent insulin release.

Fig. 3 Biological function of TG2 and the interaction with MT-2.

Fig. 5 In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig. In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig.

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Fig. 5 Simultaneous absence of caspase-3 and -7 is required for significant decrease of caspase-8 and -9 activation in intrinsic apoptosis. Simultaneous.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 5 A holistic formula TNTL targeting SBP2 in ATMs improved insulin resistance in obese mice. A holistic formula TNTL targeting SBP2 in ATMs improved.

Fig. 3 Loss of SBP2 in obesity exacerbated insulin resistance and adipogenesis. Loss of SBP2 in obesity exacerbated insulin resistance and adipogenesis.

Fig. 3 Imaging-guided S-HDL nanoimmunotherapy in rabbits and pigs: PET-based readouts. Imaging-guided S-HDL nanoimmunotherapy in rabbits and pigs: PET-based.

Fig. 2 ObR is cleaved and has reduced signaling capabilities after incubation with Mmp-2. ObR is cleaved and has reduced signaling capabilities after incubation.

Fig. 2 Loss of SBP2 induced inflammations in metabolically activated ATMs and inflammasome-associated IL-1β production. Loss of SBP2 induced inflammations.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 2. PlGF-2123–144 conjugation reduces systemic exposure to checkpoint blockade Abs and potential treatment-related toxicity. PlGF-2123–144 conjugation.

Fig. 3 LRRK2 activation in nigrostriatal dopamine neurons in two rat models of PD. LRRK2 activation in nigrostriatal dopamine neurons in two rat models.

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 2 Isopropanol-tolerant E. faecium resists disinfection.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 3. Human liver tissue seed graft function.

Tissue architecture affects function of expanded liver seed grafts

Fig. 3 Mmp-2−/− mice are protected from obesity and leptin resistance.

Fig. 1 Mmp-2 activity is increased in brains after HFD intake.

Fig. 2 Neonatal ZIKV infection induces seizures in young mice and increases susceptibility to chemically induced seizures in adult mice. Neonatal ZIKV.

Fig. 4 IP6K1-mediated polyP production by platelets plays a critical role in LPS-induced NPA formation. IP6K1-mediated polyP production by platelets plays.

Fig. 5 Increased myometrial cell contractility in response to fetal T cells from preterm infants. Increased myometrial cell contractility in response to.

Fig. 1 Study design and antibody pharmacokinetics.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. Human liver tissue seed grafts expand after host liver injury.

Fig. 1. GDF15 is up-regulated with obesity, and AAV-GDF15 improves metabolic parameters in DIO mice. GDF15 is up-regulated with obesity, and AAV-GDF15.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 3 Effects of ASO and eGLP1-ASO conjugates on gene expression and protein levels in vitro in cell lines and primary mouse islet cells. Effects of ASO.

Fig. 1. Construction of human liver seed grafts.

Fig. 7 BEL immune response.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Comparison of children’s behavior between the three conditions.

Fig. 2 Astrocyte-specific AAV2/5 RiboTag.

Presentation transcript:

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. (A) Glucose production from primary mouse hepatocytes during 45 min. Cells were preincubated in the presence or absence of 500 μM bovine serum albumin–bound palmitate followed by 24-hour incubation with or without 3 μM SFN as indicated (n = 3). (B) Left: Fasting blood glucose in male Wistar rats before and after 15 weeks of HFD feeding with or without concomitant SFN treatment [SFN (2.5 mg/kg) three times per week; n = 9 per group]. Right: Longitudinal measurements of fasting glucose during the 15-week period. P value for the blood glucose for the SFN-treated compared to control-treated rats during the 3- to 15-week period is shown. (C) IPITT after the 15-week period for the same rats as in (B). (D to G) Insulin resistance (IR) and glucose tolerance assessed in the same animals as in (B) after an additional 5 weeks on 60% HFrD or HFD with or without concomitant SFN treatment. IPGTT (D) and IPITT (E) data from rats on 60% HFrD (n = 4 to 5 per group), and IPGTT (F) and IPITT (G) data from rats on 60% HFD (n = 4 to 5 per group). (H) OGTT data from male Wistar rats fed a low-fat control diet (ctrl diet) or a 60% HFD for 11 months before and after 14 days of treatment with SFN (5 mg/kg per day) or vehicle (n = 5 HFD ctrl, n = 6 HFD SFN, and n = 8 ctrl diet). (I) OGTT in male Wistar rats with diet-induced glucose intolerance (fed 60% HFrD for 6 months) after 10 days of treatment with or without SFN (10 mg/kg per day, ip) or metformin (300 mg/kg, po) as indicated. * denotes SFN (n = 6) versus vehicle (n = 7); # denotes metformin (n = 6) versus the corresponding vehicle (n = 8). (J) IPPTT on the same rats as in (I) after 9 to 12 days of treatment with or without SFN or metformin as indicated. One-sided t test was used for statistical analysis. * denotes SFN (n = 6) versus vehicle (n = 7); # denotes metformin (n = 6) versus the corresponding vehicle (n = 7). Data are means ± SEM. *P < 0.05; **P < 0.01; #P < 0.05; ##P < 0.01. Annika S. Axelsson et al., Sci Transl Med 2017;9:eaah4477 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.